Zydus and MSN launched the first US generic of Bayer's $850M Adempas

Zydus Lifesciences, the Ahmedabad-based listed generics major; MSN Laboratories, the Hyderabad-based developer-manufacturer partnering with it in the US market.

That first-to-market positioning in complex generics — MSN develops and manufactures, Zydus sells in the US — captures the best margins before rivals arrive.

Zydus and MSN partnered on generic riociguat — Adempas, Bayer's treatment for rare pulmonary hypertension approved in the US in 2013 — with MSN responsible for development and manufacturing and Zydus overseeing commercialisation and marketing in the US.

The prize was real: Adempas amassed €745 million (around $850 million) in 2025 sales, up from €721 million, per Bayer's disclosures. The drug's patent expired in several markets in 2023 and in the US in 2026, though protection in Italy, France and Germany runs to 2028. Sharvil Patel called being first to market 'a milestone for our US business' reflecting the 'strength of our complex-generics pipeline, partnerships that complement our commercial reach'.

First-to-market generics earn outsized margins before the second entrant compresses price, so the FDA filing race was the whole game.

The partnership matched complementary strengths: MSN's complex-product development and manufacturing with Zydus's US sales and distribution.

Picking a $850M-a-year drug losing exclusivity in the world's largest market concentrated the payoff on one launch.

Sandoz's pending FDA approval left a measurable head start that only a cleared, launch-ready competitor could exploit.

In generics, the exclusivity window is the whole business — a first-mover with a partner's factory and its own salesforce earns the margin the follower never will.

The launch kicked off the generic challenge in the world's largest drug market, with Sandoz's FDA approval pending as of October 2026; Zydus said the launch reflects a complex-generics strategy built on complementary partnerships rather than going alone.